Jose Manuel Goikolea
Overview
Explore the profile of Jose Manuel Goikolea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radua J, Fortea L, Goikolea J, Zorrilla I, Bernardo M, Arrojo M, et al.
Span J Psychiatry Ment Health
. 2023 Sep;
17(4):239-250.
PMID: 37689524
Background: Individuals with bipolar disorder (BD) often have co-occurring substance use disorders (SUDs), which substantially impoverish the course of illness. Despite the importance of this dual diagnosis, the evidence of...
2.
Fernandez T, Plana T, Tardon L, Marco O, Navarro L, Bartres C, et al.
Liver Int
. 2023 Apr;
43(6):1204-1212.
PMID: 37041668
Background And Aims: Patients with severe mental disorders (SMD) have been classically considered as a particularly high-risk population for bloodborne virus infections. We performed a systematic screening of hepatitis B...
3.
Cunill R, Castells X, Gonzalez-Pinto A, Arrojo M, Bernardo M, Saiz P, et al.
Adicciones
. 2021 Jun;
34(2):168-178.
PMID: 34171106
Substantial evidence has confirmed the high comorbidity between Attention-Deficit/Hyperactivity Disorder (ADHD) and a substance use disorder (SUD). This review synthesizes the pharmacological and psychosocial interventions conducted in ADHD and SUDs,...
4.
Saiz P, Florez G, Arrojo M, Bernardo M, Gonzalez-Pinto A, Goikolea J, et al.
Adicciones
. 2021 Jun;
34(2):157-167.
PMID: 34171105
This review synthesizes the pharmacological and psychosocial interventions that have been conducted in comorbid anxiety disorders and SUDs while also providing clinical recommendations about which intervention elements are helpful for...
5.
Gonzalez-Pinto A, Goikolea J, Zorrilla I, Bernardo M, Arrojo M, Cunill R, et al.
Adicciones
. 2021 Jun;
34(2):142-156.
PMID: 34171104
This review synthesizes the pharmacological and psychosocial interventions that have been conducted in comorbid bipolar disorder (BD) and substance use disorders (SUDs) while also providing clinical recommendations about which intervention...
6.
Torrens M, Tirado-Munoz J, Fonseca F, Farre M, Gonzalez-Pinto A, Arrojo M, et al.
Adicciones
. 2021 Mar;
34(2):128-141.
PMID: 33768269
Co-occurrence of depression and a substance use disorder (SUD) in patients who present dual diagnoses has been long recognized as an important consideration in clinical practice. This review synthesizes the...
7.
Arranz B, Garriga M, Bernardo M, Gonzalez-Pinto A, Arrojo M, Torrens M, et al.
Adicciones
. 2021 Mar;
34(2):110-127.
PMID: 33768260
Although correct diagnosis and management of patients with schizophrenia and a comorbid substance use disorder (SUD) would determine a decrease in morbidity and mortality in these patients, development of efficient...
8.
Fico G, De Toffol M, Anmella G, Sague-Vilavella M, Dellink A, Verdolini N, et al.
Acta Psychiatr Scand
. 2020 Nov;
143(2):162-171.
PMID: 33140436
Objective: Seasonal pattern (SP) is a bipolar disorder (BD) specifier that indicates a tendency towards affective relapses during specific moments of the year. SP affects 15%-25% of BD patients. In...
9.
Reinares M, Pacchiarotti I, Sole B, Garcia-Estela A, Rosa A, Bonnin C, et al.
J Affect Disord
. 2020 Jul;
274:1113-1121.
PMID: 32663939
Background: The efficacy of adjunctive group psychoeducation in bipolar disorder has been proven although treatment response differ among individuals. The aim of this study was to characterize responders and non-responders...
10.
Pacchiarotti I, Tiihonen J, Kotzalidis G, Verdolini N, Murru A, Goikolea J, et al.
Eur Neuropsychopharmacol
. 2019 Feb;
29(4):457-470.
PMID: 30770235
Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance in psychoses, mainly schizophrenia spectrum disorders. We aimed to summarize available evidence of studies comparing the efficacy of LAIs to placebo...